Ajinomoto Bio-Pharma Services is significantly expanding its small molecule manufacturing capabilities with the addition of a new production facility in Visakhapatnam, India. Construction of the 8,500 square meter facility began at the end of July 2020 and is expected to be completed mid-2022.

The facility doubles the production capacity at the site to 310 m³ for active pharmaceutical ingredients (API) and intermediates and has dedicated equipment to manage OEB 4 high potency ingredients. The site has also completed renovations on existing lab space to support additional R&D activities. It’s estimated that the expansion will create at least 60 new jobs at the site.

The U.S. FDA approved Ajinomoto Bio-Pharma Services India manufacturing site, which was designed, constructed and is managed based on the Aji Bio-Pharma Belgian sites’ GMP operating standards and quality systems.

“We are very excited to be investing in this additional production capacity to continue delivering high quality, cost-effective small molecule manufacturing services for our customers,” said K.V.V. Raju, Head of Site Operations and CEO, Ajinomoto Bio-Pharma India Pvt. Ltd.